Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies

Ma SC, Tang XR, Long LL, Bai X, Zhou J, Duan ZJ, Wang J, Fu QJ, Zhu HB, Guo XJ, Zhang YP, Guo ZQ, Wu DH, Dong ZY (2021)

Publication Type: Journal article

Publication year: 2021

Journal

OncoImmunology Taylor & Francis

Book Volume: 10

Journal Issue: 1

DOI: 10.1080/2162402X.2021.1909296

Abstract

Objectives: Clinical benefits of immune-checkpoint blockade (ICB) versus standard chemotherapy have been established in unselected non-small cell lung cancer (NSCLC). However, the response to ICB therapy among patients is heterogeneous in clinical practice.

Authors with CRIS profile

Jianguo Zhou Department of Radiation Oncology

Involved external institutions

Southern Medical University / 南方医科大学 CN China (CN) Tufts University US United States (USA) (US)

How to cite

APA:

Ma, S.-C., Tang, X.-R., Long, L.-L., Bai, X., Zhou, J., Duan, Z.-J.,... Dong, Z.-Y. (2021). Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. OncoImmunology, 10(1). https://dx.doi.org/10.1080/2162402X.2021.1909296

MLA:

Ma, Si-Cong, et al. "Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies." OncoImmunology 10.1 (2021).

BibTeX: Download